GLAND2024-10-012024-12-31 GLAND2024-10-012024-12-31 GLAND2024-10-012024-12-31in-bse-fin:OneOperatingExpenses01Member GLAND2024-10-012024-12-31in-bse-fin:OneOperatingExpenses02Member GLAND2024-10-012024-12-31in-bse-fin:FourOperatingExpenses01Member GLAND2024-10-012024-12-31in-bse-fin:FourOperatingExpenses02Member GLAND2024-12-31 GLAND2024-10-012024-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member GLAND2024-10-012024-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member GLAND2024-10-012024-12-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member GLAND2024-10-012024-12-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 543245 GLAND NOTLISTED Gland Pharma Limited Equity 2024-04-01 2025-03-31 2025-02-03 2025-01-16 INR Millions Third quarter 15:00:00 17:00:00 2025-02-03 2025-02-03 Not applicable Single segment Pharmaceuticals 2024-10-01 2024-12-31 Unaudited Consolidated 13840520000.00 584940000.00 14425460000.00 4373840000.00 21470000.00 231780000.00 3428570000.00 228220000.00 963250000.00 2185310000.00 11432440000.00 2993020000.00 0.00 2993020000.00 945410000.00 690000.00 946100000.00 0.00 2046920000.00 0.00 0.00 0.00 0.00 2046920000.00 -932730000.00 1114190000.00 2046920000.00 0.00 1114190000.00 0.00 164750000.00 1 12.42 12.42 0.00 0.00 12.42 12.42 1. In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this Statement of Unaudited Consolidated Financial Results for the quarter and nine months ended December 31, 2024 ( Unaudited Consolidated Financial Results ) of Gland Pharma Limited (the Holding Company or the Company ) and its subsidiaries, (the Holding Company and its subsidiaries together referred to as the Group ) has been reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on February 3, 2025. The statutory auditors have carried out a limited review on the Unaudited Consolidated Financial Results and issued an unmodified report thereon. 2. The Unaudited Consolidated Financial Results of the Group have been prepared in accordance with the Indian Accounting Standards notified under Section 133 of the Companies Act 2013, as amended and read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the Listing requirements ). 3. The Group is engaged in the manufacture and sale of Pharmaceuticals which constitutes a single reportable business segment as per Ind AS 108- 'Operating Segments'. Refer the signed results uploaded for the complete notes. Single segment 2024-04-01 2024-12-31 Unaudited Consolidated 41915950000.00 1695790000.00 43611740000.00 13849130000.00 113890000.00 2061270000.00 10281940000.00 345500000.00 2821130000.00 6395630000.00 35868490000.00 7743250000.00 0.00 7743250000.00 2682360000.00 -58960000.00 2623400000.00 0.00 5119850000.00 0.00 0.00 0.00 0.00 5119850000.00 -91390000.00 5028460000.00 5119850000.00 0.00 5028460000.00 0.00 164750000.00 1 31.08 31.08 0.00 0.00 31.08 31.08 Other expenses 1638720000.00 Power and fuel 546590000.00 Other expenses 4930110000.00 Power and fuel 1465520000.00 Remeasurement of defined benefit plans -22310000.00 Remeasurement of defined benefit plans -7450000.00 -22310000.00 -7450000.00 -5810000.00 -2070000.00 Exchange differences on translation of foreign operations -916230000.00 Exchange differences on translation of foreign operations -86010000.00 -916230000.00 -86010000.00 0.00 0.00